DeepMed Research

ICAHN School of Medicine At Mount Sinai

🇺🇸United States

Country: 🇺🇸United States

Ownership: Private, Subsidiary

Established: 1963-01-01

Employees: 5K

Market Cap: -

Website: http://www.mssm.edu

Clinical Trials

An Intuitive, Non-intrusive, Approach to Reduce Patient Harm From Inappropriate Dosing of High-risk Drugs in Older Adult Patients Across an Urban Safety Net Hospital System

Not Applicable

Completed

Conditions: Potentially Inappropriate Medications

Interventions: Behavioral: EHR-based "nudge" interventions

First Posted Date: 2022-02-01

Last Posted Date: 2023-03-17

Lead Sponsor: Icahn School of Medicine at Mount Sinai

Target Recruit Count: 8640

Registration Number: NCT05218343

Locations: 🇺🇸
Icahn School of Medicine at Mount Sinai, New York, New York, United States
🇺🇸
NYC Health+Hospitals, New York, New York, United States

Microcurrent Device (TIVIC Health)

Not Applicable

Completed

Conditions: Chronic Rhinosinusitis

Interventions: Device: Microcurrent TENS device
Device: Sham Device

First Posted Date: 2022-01-20

Last Posted Date: 2024-08-13

Lead Sponsor: Icahn School of Medicine at Mount Sinai

Target Recruit Count: 60

Registration Number: NCT05198518

Locations: 🇺🇸
Faculty Practice Associates - Mount Sinai Doctors, New York, New York, United States

Metabolic Diet for Relapse Prevention in Anorexia Nervosa

Not Applicable

Recruiting

Conditions: Anorexia Nervosa

Interventions: Dietary Supplement: Metabolic Diet

First Posted Date: 2022-01-19

Last Posted Date: 2025-02-04

Lead Sponsor: Icahn School of Medicine at Mount Sinai

Target Recruit Count: 20

Registration Number: NCT05197309

Locations: 🇺🇸
Icahn School of Medicine at Mount Sinai, New York, New York, United States

Rapid Sequencing of Approved Therapies in Patients with Metastatic or Unresectable Clear Cell Renal Cell Carcinoma

Early Phase 1

Recruiting

Conditions: Renal Cell Carcinoma

Interventions: Drug: Cabozantinib
Drug: Ipilimumab
Drug: Nivolumab
Drug: Lenvatinib
Drug: Everolimus

First Posted Date: 2022-01-12

Last Posted Date: 2024-11-06

Lead Sponsor: Icahn School of Medicine at Mount Sinai

Target Recruit Count: 20

Registration Number: NCT05188118

Locations: 🇺🇸
Icahn School of Medicine at Mount Sinai, New York, New York, United States

A Controlled Trial of Growth Hormone in Phelan-McDermid Syndrome and Idiopathic Autism

Phase 2

Completed

Conditions: Autism Spectrum Disorder (ASD)
Phelan-McDermid Syndrome

Interventions: Drug: Saline
Drug: Growth Hormone

First Posted Date: 2022-01-11

Last Posted Date: 2025-04-20

Lead Sponsor: Icahn School of Medicine at Mount Sinai

Target Recruit Count: 32

Registration Number: NCT05187377

Locations: 🇺🇸
Seaver Autism Center for Research & Treatment, New York, New York, United States

Sensation, Motion, and Quality of Life on Natalizumab and Off Natalizumab

Not Applicable

Withdrawn

Conditions: Relapsing-remitting Multiple Sclerosis (RRMS)

Interventions: Device: BeCare application

First Posted Date: 2021-12-29

Last Posted Date: 2022-11-25

Lead Sponsor: Icahn School of Medicine at Mount Sinai

Registration Number: NCT05172466

Locations: 🇺🇸
Mount Sinai Hospital, New York, New York, United States

Environmental Factors and Thyroid Cancer

Recruiting

Conditions: Thyroid Cancer

First Posted Date: 2021-12-29

Last Posted Date: 2024-08-19

Lead Sponsor: Icahn School of Medicine at Mount Sinai

Target Recruit Count: 500

Registration Number: NCT05172921

Locations: 🇺🇸
Icahn School of Medicine at Mount Sinai, New York, New York, United States

Connectomic Deep Brain Stimulation for Obsessive Compulsive Disorder

Not Applicable

Suspended

Conditions: Obsessive Compulsive Disorder (OCD)

Interventions: Device: Selective focal stimulation of ALIC-pathways

First Posted Date: 2021-12-16

Last Posted Date: 2025-04-13

Lead Sponsor: Icahn School of Medicine at Mount Sinai

Target Recruit Count: 20

Registration Number: NCT05160129

Locations: 🇺🇸
Mount Sinai West, New York, New York, United States

ERTU-SODIUM: Study on the Effects of Ertugliflozin on Sodium Storage, Interstitial Volume, and Plasma Volume in HFrEF

Phase 4

Recruiting

Conditions: Congestion
Heart Failure With Reduced Ejection Fraction

Interventions: Drug: Ertugliflozin
Drug: Placebo

First Posted Date: 2021-12-10

Last Posted Date: 2023-10-13

Lead Sponsor: Icahn School of Medicine at Mount Sinai

Target Recruit Count: 28

Registration Number: NCT05152940

Locations: 🇺🇸
Icahn School of Medicine at Mount Sinai, New York, New York, United States

Gondola Mechanism of Action

Not Applicable

Withdrawn

Conditions: Chronic Stroke
Cerebral Palsy
Parkinson's Disease

Interventions: Device: Gondola AMPS

First Posted Date: 2021-12-07

Last Posted Date: 2023-01-18

Lead Sponsor: Icahn School of Medicine at Mount Sinai

Registration Number: NCT05146648

Locations: 🇺🇸
Abilities Research Center, New York, New York, United States

© Copyright 2025. All Rights Reserved by MedPath

Home Terms & Conditions Privacy Policy